Journal
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
Volume 45, Issue 2, Pages 156-159Publisher
SLACK INC
DOI: 10.3928/23258160-20140124-01
Keywords
-
Categories
Funding
- Actelion
- Gilead
- United Therapeutics
- Lung Rx
- Pfizer
- Merck
- Ikaria
Ask authors/readers for more resources
Ambrisentan (Letairis; Gilead Sciences, Foster City, CA) is an endothelin receptor antagonist approved by the U. S. Food and Drug Administration for the treatment of pulmonary arterial hypertension. The authors describe the occurrence of bilateral cotton wool spots soon after initiation of ambrisentan treatment in a 29-year-old woman. Fluorescein angiography, optical coherence tomography, and fundus autofluorescence were performed. After discontinuation of ambrisentan, the cotton wool spots resolved without recurrence. To the authors' knowledge, this is the first report of retinopathy in the form of cotton wool spots associated with the use of an endothelin receptor antagonist.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available